Celerion, a specialist in early clinical research, has appointed Bruce Morimoto as Executive Director of Applied Translational Medicine. He takes responsibility for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies. He will also lead the External Studies Management and Clinical Monitoring Services teams.
Celerion is focused on translating information gained in research discoveries to knowledge of drug action and its effect in humans to support early drug development decisions and the clinical pharmacology labelling of new medicines.
Morimoto has more than 20 years of experience in the pharmaceutical and biotechnology industries as well as in contract research organisations (CRO).
Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics. He also worked for contract research organisation MDS Pharma Services; Neuromed Technologies, a biotech company developing novel pain therapeutics; Phoenix International Life Sciences, a global CRO; and Amur Pharmaceuticals, a biopharmaceutical company focused on diabetes and drug delivery research.
